VIENNA—Three key targetable pathways for breast cancer treatment were assessed at the St Gallen Breast Cancer Conference by Clifford Hudis, MD, Chief of the Breast Medicine Service at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York. He gave Oncology Times reporter Sarah Maxwell his review of the clinical usefulness of targeting the CDK 4-6, PIK3CA and FGFR pathways.
You may also like...
Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes 26 Mar, 2015 Pembrolizumab: No Survival Gains Second Line In Gastric Cancer 18 Oct, 2018 Radiotherapy Triggers Durable Immunotherapy Responsiveness Beyond Radiation Field 24 Aug, 2016 Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer 12 Feb, 2014
- Previous story Breast Cancer Prognostic Implications of Obesity and Insulin Resistance
- Next story No Prime Time Soon for Vaccines in Lung Cancer—Immune Suppression Reversal Urgently Needed
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014